Baker Bros. Advisors Lp bought $172.5M of Kymera Therapeutics (KYMR)
Executed Dec 11 2025, disclosed Dec 11 2025, the same day.
Over the 21 trading sessions from the disclosed entry session (Dec 11 2025), the stock returned -19.5% (delay-adjusted); from the execution session (Dec 11 2025), -19.5%. Derived: entry at the session's open, exit at the close 20 sessions later.
Baker Bros. Advisors Lp (Other) filed 5 Form 4 reports as a reporting entity in the trailing twelve months (4 purchases, 1 sale), most often in Celcuity Inc. (CELC). Across 4 priced purchase filings, the average 21-session return was +14.0% from execution and +7.3% from disclosure (delay-adjusted; derived). The largest single filing was $317.8M of CELC (3,100,000 sh across 2 lots, as filed), executed Jul 14.
Healthcare · Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→